Payers addicted to addiction, says Pops, as Alkermes shows sustained opiate abstinence
This article was originally published in Scrip
Alkermes has reported that an open-label extension of its pivotal six-month trial for Vivitrol for opioid dependence, in combination with counselling, shows sustained efficacy and safety over 18 months. But sales of the drug, approved in the US since October 2010 to prevent relapse to opioid dependence following opioid detoxification, remain slow. This prompted Alkermes CEO Richard Pops to suggest that part of the problem for Alkermes is that health insurers are hooked on paying for opioid substitutes which maintain, rather than reverse, opioid dependence.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.